Ultrasmall Superparamagnetic Iron Oxide to Enhance MRA of the Renal and Coronary Arteries: Studies in Human Patients

Stillman, Arthur E.; Wilke, Norbert; Li, Debiao; Haacke, E. Mark; McLachlan, Stuart J.

doi:10.1097/00004728-199601000-00011

Cited by 109 publications

(67 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous preclinical and several clinical studies describe their use both in MRA of individual vascular territories, such as pulmonary arteries [96], the aorta [80,97], coronary arteries [10,98,99], renal arteries [10], mesenterial and portal veins [100], hepatic veins [101], and the inferior vena cava [102], as well as in whole-body angiography of arteries and veins for assessing stenoses and thromboses [103]. Potential USPIO for clinical application are Supravist ® (SHU 555C, phase I, Bayer Healthcare Pharmaceuticals), AMI-227 (Sinerem ® , phase III), and VSOP-184 (phase I).…”

Section: T1 Applications Magnetic Resonance Angiography (Mra)mentioning

confidence: 99%

“…As a result of systematic further development of SPIO, in particular size variation and coating modifications, numerous additional areas of application in preclinical and clinical MR diagnostics have been tested in the last two decades. Therefore, SPIO have been frequently tested in preclinical feasibility studies as a T1 contrast agent for MR angiography in vascular diagnostics [10], as a T2 or T2* contrast agent for the detection of atherosclerotic plaques [11] and vascular thrombi [12], in perfusion diagnosis of tumors [13], myocardium [14], renal parenchyma [15], vital brain [16], cerebral ischemia [17], and the placenta [18], and in the diagnosis of synovial structures, e. g. in the knee [19]. Newer applications in the primarily still preclinical experimental field of molecular imaging describe on a cellular level the in vitro labeling of cell types (e. g. macrophages, lymphocytes, progenitor/stem cells) with SPIO (cell labeling) and their diagnostic in vivo MR imaging and migration tracking (tracking/migration monitoring) [20,21].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and Therapy

Ittrich¹,

Peldschus²,

Raabe³

et al. 2013

Fortschr Röntgenstr

123

101

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles (SPIO) can be used to image physiological processes and anatomical, cellular and molecular changes in diseases. The clinical applications range from the imaging of tumors and metastases in the liver, spleen and bone marrow, the imaging of lymph nodes and the CNS, MRA and perfusion imaging to atherosclerotic plaque and thrombosis imaging. New experimental approaches in molecular imaging describe undirected SPIO trapping (passive targeting) in inflammation, tumors and associated macrophages as well as the directed accumulation of SPIO ligands (active targeting) in tumor endothelia and tumor cells, areas of apoptosis, infarction, inflammation and degeneration in cardiovascular and neurological diseases, in atherosclerotic plaques or thrombi. The labeling of stem or immune cells allows the visualization of cell therapies or transplant rejections. The coupling of SPIO to ligands, radio- and/or chemotherapeutics, embedding in carrier systems or activatable smart sensor probes and their externally controlled focusing (physical targeting) enable molecular tumor therapies or the imaging of metabolic and enzymatic processes. Monodisperse SPIO with defined physicochemical and pharmacodynamic properties may improve SPIO-based MRI in the future and as targeted probes in diagnostic magnetic resonance (DMR) using chip-based ?NMR may significantly expand the spectrum of in vitro analysis methods for biomarker, pathogens and tumor cells. Magnetic particle imaging (MPI) as a new imaging modality offers new applications for SPIO in cardiovascular, oncological, cellular and molecular diagnostics and therapy. Key Points: Citation Format:

show abstract

Section: T1 Applications Magnetic Resonance Angiography (Mra)mentioning

confidence: 99%

mentioning

confidence: 99%

Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and Therapy

Ittrich¹,

Peldschus²,

Raabe³

et al. 2013

Fortschr Röntgenstr

123

101

View full text Add to dashboard Cite

show abstract

“…These features allow for extensive signal averaging to improve the intravascular signal-to-noise ratio (SNR) and thereby permit images with much higher spatial resolution to be obtained than would be feasible using extracellular agents (10 -19). However, equilibrium images acquired over many minutes show both arterial and venous contrast enhancement, which complicates the interpretation of the vasculature (14).…”

mentioning

confidence: 99%

First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agent

Li¹,

Tutton²,

Vu³

et al. 2004

Magnetic Resonance Imaging

207

139

View full text Add to dashboard Cite

Purpose:To evaluate the feasibility of first-pass contrastenhanced magnetic resonance angiography (MRA) using ferumoxytol in humans. Materials and Methods:First-pass and equilibrium phase MRA were performed using ferumoxytol in one healthy volunteer and 11 patients with a fast three-dimensional spoiled gradient recalled (SPGR) pulse sequence. The examined vessels included carotid arteries, thoracic aorta, abdominal aorta, and peripheral arteries. A dose of either 71.6 mol Fe/kg (n ϭ 9), or 35.8 mol Fe/kg (n ϭ 3) was used. Based on a phantom study, the agent with initial concentration of 537.2 mol Fe/mL was diluted by either four-fold (134.3 mol Fe/mL) or eight-fold (67.1 mol Fe/ mL) for first-pass MRA.Results: All subjects completed their studies without adverse events. First-pass MRA showed selective arterial enhancement, with both arterial and venous enhancement on delayed acquisitions. Selective venous enhancement could be obtained by subtraction of arterial phase images from equilibrium phase images. The findings in ferumoxytol MRA were consistent with the results of original vascular tests. Conclusion:Our preliminary experience supports the feasibility of first-pass MRA with ferumoxytol. Satisfactory arterial enhancement during first-pass imaging is obtained with injection of diluted contrast agent. With ferumoxytol, arteries and veins can be selectively depicted in a single exam.

show abstract

“…CLARISCAN has the advantage that it is strictly intravascular and is therefore well suited for renal perfusion studies (14). Another contrast agent under clinical investigation is AMI 227 (Combidex or Sinerem), which has imaging properties similar to those of CLARISCAN (15,16).…”

Section: Discussionmentioning

confidence: 99%

Deep venous thrombosis and consecutive pulmonary embolism as the first sign of an ovarian cancer: MR angiography using an intravascular contrast agent (CLARISCAN)

Sandstede

Krause

Pabst

et al. 2000

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

Ultrasmall Superparamagnetic Iron Oxide to Enhance MRA of the Renal and Coronary Arteries: Studies in Human Patients

Abstract: These studies support the hypothesis that 3D MRA in the body will benefit from the use of intravascular contrast agents. Nevertheless, conventional MIP processing is unable to reveal the full advantage of the contrast improvement.

Cited by 109 publications

References 13 publications

Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and Therapy

Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and Therapy

First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agent

Deep venous thrombosis and consecutive pulmonary embolism as the first sign of an ovarian cancer: MR angiography using an intravascular contrast agent (CLARISCAN)

Contact Info

Product

Resources

About